

·PTO/SB/13/PCT (10-00)

es.

Approved for use through 10/31/2002. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REQUEST FOR FILING A CONTINUATION OR DIVISION OF AN INTERNATIONAL APPLICATION

•					<u> 7</u>	
DOCKET NUMBER	ANTICIPATED OF THIS APPL		PRIOR APPLICATION EXAMINER	ART UNIT	2660	
GA0150C	CLASS	SUBCLASS			160 160 160 160 160 160 160 160 160 160	

Address to:

Assistant Commissioner for Patents Washington, D.C. 20231

internation	equest for filing a 🛭 al application Numbe ENES DIFFERENTIAL	r PCT <u>US99/2316</u>	, file	ed on <u>04</u>	October 1999 entit	
				_, which desi	gnated the United Sta	ates
	R 1.53(d) cannot be used thational stage.	o file a continuation or di	visional application of an	international ap	oplication which has not	
CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS	ļ
2	TOTAL CLAIMS (37 CFR 1.16(c))	24 - 20 =	4	x <u>18</u> =	\$ 72.00	
	INDEPENDENT CLAIMS (37 CFR 1.16(b))		2	x <u>80</u> =	160.00	
a di eseda	MULTIPLE DEPENDEN	T CLAIMS (if applicable)	(37 CFR	+ 270 =	270.00	
	1. 3.1950 J. 1. <b>37</b> 1. 3.		BASIC I (37 CFR 1.		+. 710.00	
	- 1 - 44 · 1/4 · 1/4		Total of above Calcula	itions =	1,212.00	
	Reduction by 50% for fi	ing by small entity (Note	37 CFR		0.00	
3.00				<b>-</b>	¢1 010 00	

- 1. Enclosed are the specification, claims and drawing(s).
- 2. 🗆 Applicant claims small entity status. See 37 CFR 1.27.
- The Commissioner is hereby authorized to charge any fees which may be required under 37 CFR 1.16 and 1.17, or credit any overpayment to Deposit Account No. \_\_\_\_\_\_\_\_. A duplicate copy of this sheet is 3. 🔯 enclósed.
- 4. 🔲 A check in the amount of \$ \_\_\_\_\_ is enclosed.
- 5. Payment by credit card. Form PTO-2038 is attached.
- 6. 🛛 Application Data Sheet is enclosed. See 37 CFR 1.76.

7. 🛛	Amend the specification by inserting before the first	line the sentence:	This application is a	continuation
	division of international application number PCT			ctober 1999 .
	(status, abandoned, pending, etc.)."			

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.5 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/13/PCT (10-00)

Approved for use through 10/31/02. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR FILING A CONTINUATION OR D	DIVISION OF AN INTERNATIONAL APPLICATION
8. 🛮 A declaration under 37 CFR 1.63 is enclosed.	
<ol> <li>Priority of foreign application number</li></ol>	, filed on in
☐ The certified copy is enclosed.	
10. A preliminary amendment is enclosed.	
11. Also enclosed: Return Postcard	·
Address all future correspondence to: (May only be co	ompleted by applicant, or attorney or agent of record).
Elizabeth Lassen, Genzyme Corporation, 15 Pleasant Street C	
Framingham, Massachusetts 01701-9322	
	Cara de l
4/5/01	Elijaluth Jana
<b>Date</b>	Signature
	Elizabeth Lassen
	Typed or printed name
	•
Inventor(s)/Applicant(s)	
Assignee of the entire interest. See 37 C under 37 CFR 3.73(b) is enclosed. (Form	
Attorney or agent of record	
Filed under 37 CFR 1.34(a) Registration number if acting under 37 CFR 1.34(a)	a)
NOTE: Signatures of all the inventors or assignees of record of Submit multiple forms if more than one signature is required, s	
*Total of forms are submitted.	

			D 1 1N-
	IAILIN "EXPRESS M	AIL" (37 CFR 1.1	Docket No.
oplicant(s): ROBERTS,	et al.		GA0150C
Serial No.	Filing Date	Examiner	Group Art Unit
Unassigned	April 5, 2001	Unassigned	Unassigned
vention: GENES DIFFI	ERENTIALLY EXPRESSED IN	CANCER CELLS TO DESIGN (	CANCER VACCINES
I hereby certify that the t	following correspondence:		
Data Sheet; Unexecuted	ontinuation of an International A Declaration for Utility or Design I Formal Drawing (1 sheet); and a l	Patent Application (37 CFR 1.63	
	(Identify type of	correspondence)	
37 CFR 1.10 in an enve April 5, 2 (Date)	lope addressed to: The Assistan	TARYN ANTAI	ashington, D.C. 20231 on
		(Typed or Printed Name of Person Mailing Co (Signature of Person Mailing Co EL 826 463 585 ("Express Mail" Mailing Lab	ling Correspondence) HACLE  prespondence) US